Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 17 | 2022 | 328 | 2.300 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2024 | 162 | 1.390 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2022 | 67 | 1.340 |
Why?
|
| Graft vs Host Disease | 6 | 2022 | 99 | 1.140 |
Why?
|
| Transplantation Conditioning | 10 | 2018 | 94 | 0.910 |
Why?
|
| Clostridium Infections | 1 | 2022 | 46 | 0.790 |
Why?
|
| Multiple Myeloma | 7 | 2020 | 323 | 0.650 |
Why?
|
| Leukemia | 2 | 2016 | 53 | 0.540 |
Why?
|
| Transplantation, Homologous | 7 | 2022 | 233 | 0.370 |
Why?
|
| Myeloablative Agonists | 3 | 2015 | 13 | 0.360 |
Why?
|
| Dendritic Cells | 1 | 2013 | 508 | 0.330 |
Why?
|
| Amyloidosis | 2 | 2020 | 58 | 0.290 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2021 | 51 | 0.290 |
Why?
|
| Mitoxantrone | 2 | 2018 | 17 | 0.290 |
Why?
|
| Busulfan | 2 | 2018 | 10 | 0.280 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2019 | 68 | 0.270 |
Why?
|
| Adult | 21 | 2024 | 15762 | 0.260 |
Why?
|
| Disease-Free Survival | 9 | 2017 | 233 | 0.260 |
Why?
|
| Stem Cell Transplantation | 3 | 2020 | 75 | 0.250 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 170 | 0.240 |
Why?
|
| Melphalan | 2 | 2015 | 22 | 0.240 |
Why?
|
| Staurosporine | 1 | 2024 | 19 | 0.230 |
Why?
|
| Dioxygenases | 1 | 2024 | 25 | 0.220 |
Why?
|
| Aged | 19 | 2024 | 13334 | 0.220 |
Why?
|
| Humans | 31 | 2024 | 59422 | 0.210 |
Why?
|
| Mutation | 4 | 2024 | 2443 | 0.200 |
Why?
|
| Transplantation, Autologous | 6 | 2020 | 118 | 0.200 |
Why?
|
| Middle Aged | 19 | 2024 | 16248 | 0.190 |
Why?
|
| Male | 22 | 2024 | 27545 | 0.190 |
Why?
|
| Incidence | 2 | 2022 | 1238 | 0.190 |
Why?
|
| Strongyloides stercoralis | 1 | 2020 | 12 | 0.170 |
Why?
|
| Strongyloidiasis | 1 | 2020 | 10 | 0.170 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2020 | 12 | 0.170 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 143 | 0.170 |
Why?
|
| Survival Analysis | 6 | 2018 | 553 | 0.170 |
Why?
|
| Child | 5 | 2022 | 4306 | 0.170 |
Why?
|
| Female | 21 | 2024 | 30883 | 0.170 |
Why?
|
| Retrospective Studies | 6 | 2022 | 6000 | 0.170 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 94 | 0.160 |
Why?
|
| Treatment Outcome | 10 | 2020 | 5170 | 0.160 |
Why?
|
| Adolescent | 11 | 2018 | 5918 | 0.160 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 5095 | 0.160 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 33 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 220 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 46 | 0.150 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 41 | 0.150 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 1131 | 0.150 |
Why?
|
| Bone Marrow Transplantation | 2 | 2016 | 133 | 0.150 |
Why?
|
| Vascular Diseases | 1 | 2018 | 69 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 645 | 0.140 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2017 | 19 | 0.140 |
Why?
|
| Databases, Factual | 5 | 2021 | 839 | 0.140 |
Why?
|
| Allografts | 4 | 2018 | 44 | 0.140 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2016 | 21 | 0.130 |
Why?
|
| Virus Activation | 1 | 2016 | 24 | 0.130 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2015 | 17 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 404 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 31 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 1 | 2016 | 69 | 0.120 |
Why?
|
| Cytomegalovirus | 1 | 2016 | 88 | 0.120 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 71 | 0.120 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 160 | 0.120 |
Why?
|
| Metabolic Syndrome | 1 | 2016 | 148 | 0.120 |
Why?
|
| Young Adult | 7 | 2018 | 4316 | 0.110 |
Why?
|
| Whole-Body Irradiation | 2 | 2014 | 31 | 0.110 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2014 | 33 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 99 | 0.110 |
Why?
|
| Recurrence | 4 | 2017 | 577 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2014 | 174 | 0.110 |
Why?
|
| Immunotherapy | 2 | 2020 | 231 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 26 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2017 | 1912 | 0.100 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 46 | 0.100 |
Why?
|
| Survival Rate | 4 | 2017 | 790 | 0.100 |
Why?
|
| Quality of Life | 1 | 2018 | 1118 | 0.100 |
Why?
|
| Infant | 4 | 2018 | 1523 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 201 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 453 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 276 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 386 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2018 | 1839 | 0.090 |
Why?
|
| Parotitis | 1 | 2009 | 1 | 0.080 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2024 | 25 | 0.080 |
Why?
|
| Anemia, Aplastic | 1 | 2009 | 10 | 0.080 |
Why?
|
| Lymphocyte Transfusion | 1 | 2009 | 37 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 820 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2009 | 259 | 0.070 |
Why?
|
| Remission Induction | 2 | 2018 | 137 | 0.070 |
Why?
|
| Age Factors | 3 | 2018 | 1516 | 0.070 |
Why?
|
| Risk Factors | 4 | 2018 | 5011 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 155 | 0.070 |
Why?
|
| Disease Progression | 2 | 2024 | 1045 | 0.060 |
Why?
|
| Stem Cells | 1 | 2007 | 257 | 0.060 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 28 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 354 | 0.060 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 82 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 315 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2024 | 336 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2021 | 53 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1293 | 0.050 |
Why?
|
| Electronics | 1 | 2021 | 37 | 0.050 |
Why?
|
| Bortezomib | 1 | 2020 | 55 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2020 | 48 | 0.040 |
Why?
|
| Thiabendazole | 1 | 2020 | 3 | 0.040 |
Why?
|
| Enterococcus faecium | 1 | 2020 | 6 | 0.040 |
Why?
|
| Antiparasitic Agents | 1 | 2020 | 6 | 0.040 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2020 | 13 | 0.040 |
Why?
|
| Daptomycin | 1 | 2020 | 9 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2020 | 32 | 0.040 |
Why?
|
| Ivermectin | 1 | 2020 | 10 | 0.040 |
Why?
|
| Abdomen | 1 | 2020 | 89 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2020 | 64 | 0.040 |
Why?
|
| Imatinib Mesylate | 1 | 2019 | 32 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 299 | 0.040 |
Why?
|
| Neoplasms | 1 | 2009 | 1244 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 301 | 0.040 |
Why?
|
| Autografts | 1 | 2017 | 7 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 161 | 0.040 |
Why?
|
| Time Factors | 2 | 2016 | 3577 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2016 | 12 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2016 | 30 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2016 | 27 | 0.030 |
Why?
|
| Probability | 1 | 2017 | 172 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2016 | 24 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 55 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2016 | 99 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2015 | 12 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 200 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 990 | 0.030 |
Why?
|
| Karyotype | 1 | 2015 | 16 | 0.030 |
Why?
|
| Siblings | 1 | 2014 | 45 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 59 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 961 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2014 | 8 | 0.030 |
Why?
|
| Syndecan-1 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2016 | 318 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2016 | 305 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 344 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1094 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2016 | 314 | 0.030 |
Why?
|
| Echocardiography | 1 | 2016 | 459 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 28 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2012 | 32 | 0.030 |
Why?
|
| Cytarabine | 1 | 2012 | 34 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 375 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 1090 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2012 | 188 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 804 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 847 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 1548 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 925 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1027 | 0.020 |
Why?
|
| Massachusetts | 1 | 2016 | 2095 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1572 | 0.020 |
Why?
|
| Transplantation Chimera | 1 | 2009 | 37 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2009 | 64 | 0.020 |
Why?
|
| Prednisone | 1 | 2009 | 80 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1448 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2009 | 169 | 0.020 |
Why?
|
| Heart Failure | 1 | 2016 | 867 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 2443 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 159 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 506 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 2007 | 18 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 19641 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 3095 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 182 | 0.020 |
Why?
|
| Interphase | 1 | 2007 | 66 | 0.020 |
Why?
|
| S Phase | 1 | 2007 | 76 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 903 | 0.020 |
Why?
|
| Pluripotent Stem Cells | 1 | 2007 | 67 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 231 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 155 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2007 | 249 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 178 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2007 | 379 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 2327 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2007 | 1456 | 0.010 |
Why?
|
| Mice | 1 | 2007 | 10272 | 0.010 |
Why?
|